Last edition
News about Market
BioMarin to Acquire Alesta Therapeutics for Oral Hypophosphatasia Therapy ALE1
BioMarin will acquire Alesta Therapeutics for USD 275 million upfront, gaining ALE1, a potential first oral therapy for hypophosphatasia, plus milestone payments.
Market | 20/08/2026 | By News Bureau | 120
Roche Canada Completes pCPA Negotiations for Perjeta in Early HER2-Positive Breast Cancer
Roche Canada has completed pCPA negotiations for Perjeta in combination with trastuzumab and chemotherapy for eligible patients with HER2-positive early-stage breast cancer, bringing the treatment closer to potential public reimbursement across Canada.
Market | 20/08/2026 | By News Bureau
LEO Pharma has agreed to acquire worldwide rights to Tanabe Pharma’s oral MC1R agonist dersimelagon for up to USD 435 million in upfront and near-term milestones, strengthening its rare dermatology pipeline for EPP and XLP.
Market | 19/08/2026 | By News Bureau | 118
Sandoz and Henlius Partner on up to 10 Biosimilars
Sandoz partners with Henlius on up to 10 biosimilars, expanding its pipeline to 39 assets with potential to reach 46, including cetuximab, evolocumab and belimumab.
Market | 19/08/2026 | By News Bureau
Life Couriers Completes Acquisition by JLL Partners
Life Couriers completes its acquisition by JLL Partners and appoints healthcare logistics executive Edward DeMartini as CEO to drive growth and expansion.
Market | 19/08/2026 | By News Bureau | 118
Piramal Pharma Acquires 40.67 Percent Additional Stake in Yapan Bio for INR 76 Crore
Piramal Pharma acquires an additional 40.67 percent stake in Yapan Bio for INR 76 crore, raising its ownership to 74 percent and expanding its biologics Contract Development and Manufacturing Organisation (CDMO) capabilities.
Market | 18/08/2026 | By News Bureau | 162
OmniAb and Eli Lilly Partner on Ion Channel Program
OmniAb and Eli Lilly enter a global collaboration for an ion channel program, leveraging OmniAb’s technology platform and expertise in ion channel discovery and screening.
Market | 17/08/2026 | By News Bureau | 168
Pharming Launches Joenja in Japan for APDS Patients Aged 4 and Older
Pharming has launched Joenja in Japan for APDS patients aged 4 years and older, making Japan the first market to offer the treatment commercially to children aged 4–11.
Market | 14/08/2026 | By News Bureau | 125
Tris Pharma Partners with Calm Health, ADHD Central to Expand Support for ADHD Patients
Tris Pharma has partnered with Calm Health and ADHD Central to complement ADHD treatment with mental wellness, organisation and productivity resources for patients and caregivers.
Market | 14/08/2026 | By News Bureau
Tasman Therapeutics and Osmind Partner to Advance R-107 for Depressive Disorders
Tasman Therapeutics and Osmind are partnering to advance R-107, an investigational oral extended-release ketamine therapy, through phase 3 trials for depressive disorders.
Market | 13/08/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy